IL2 and triple-A syndrome: Experimental evidence from established AAA models demonstrates that targeted inhibition of IL‐12 in elastase‐perfusion models and IL‐2 blockade in angiotensin II (Ang II)‐infusion models significantly attenuates disease progression, highlighting cytokine‐specific therapeutic potential [26, 27].